The promoter of JB Chemicals & Pharmaceuticals Ltd. sold 5.8% stake in the company for Rs 1,460 crore through an open market transaction on Thursday.
The New York and Hong Kong-based investment firm— Tau Investment Holdings offloaded 89.83 lakh shares or 5.8% at Rs 1625 apiece, according to a bulk deal data on NSE.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Tau Investment held 53.66% in the company as of December 2024.
Kotak Mahindra Mutual Fund mopped up 12.3 lakh shares or 0.79% stake at Rs 1,625 apiece.
On Wednesday, sources informed NDTV Profit that the pharmaceutical firm will sell up to 15.9 million shares in a block valued at Rs 2,576 crore. The shares were to be offered at a price of Rs 1,625 apiece, the sources had said.
In the quarter ended December 2024, JB Chemicals' consolidated net profit jumped 22% year-on-year to Rs 163 crore. The revenue grew 14% to Rs 963 crore in the same period.
Shares of JB Chemicals on Thursday closed 5.45% lower at Rs 1,615.70 apiece on the National Stock Exchange, compared to a 0.45% rise in the benchmark Nifty 50. The stock has fallen by 1.66% in the last 12 months but declined 12.39% on a year-to-date basis.
Thirteen out of the 15 analysts tracking the company have a 'buy' rating on the stock, one recommends 'hold' and another suggests 'sell', according to Bloomberg data. The average of 12-month analysts' price targets implies a potential upside of 33%.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.